Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
JAMA 293:2496-2500, Levin,L.I.,et al, 2005
Epstein-Barr Virus in Pediatric Multiple Sclerosis
JAMA 291:1875-1879, Alotaibi,S.,et al, 2004
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis
JAMA 286:3083-3088,3127, Ascherio,A.,et al, 2001
Diagnosis of AIDS-Related Focal Brain Lesions
Neurol 48:687-694, Antinori,A.,et al, 1997
Cerebrospinal Fluid
JNNP 59:349-357, Thompson,E.J., 1995
Tick-Borne Encephalitis
Lancet 371:1861-1871, Lindquist,L. &Vapalahti,O., 2008
Pediatric Encephalitis: What Is the Role of Mycoplasma Pneumoniae
Pediatrics 120:305-313, Christie,L.J., et al, 2007
Acute Viral Encephalitis in Childhood
BMJ 310:139-140, Kennedy,C., 1995
Campylobacter Jejuni Infection and Guillain-Barre Syndrome
NEJM 333:1374-1379, 14151995., Rees,J.H.,et al, 1995